Allopurinol Cuts Heart Attack, Stroke Risk in Gout
SkimNews Take
The cardiovascular benefit tracks with hitting the existing 360 µmol/L rheumatology target rather than allopurinol exposure per se, hinting that uric acid itself — not just gout — is the modifiable risk factor.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Nottingham led a large‑scale observational study, published in JAMA Internal Medicine, that examined whether achieving serum urate <360 µmol/L with allopurinol lowers cardiovascular events.
- Clinical Practice Research Datalink Aurum supplied primary‑care records for nearly 110,000 gout patients aged 18+ from Jan 2007–Mar 2021, linked to hospital and mortality data.
- Participants who reached the urate target (<360 µmol/L) within 12 months experienced a lower five‑year incidence of major adverse cardiovascular events—heart attack, stroke, or cardiovascular death—than those who did not.
- High‑risk patients showed an especially strong protective effect, and those who lowered urate to <300 µmol/L saw even greater risk reductions.
- Allopurinol therapy also resulted in fewer gout flares among patients who achieved the urate target.
- Emulated target trial methodology allowed researchers to assess outcomes efficiently without a traditional randomized trial.
Why it matters: Gout patients who achieve the recommended urate level gain a measurable survival advantage, especially those already at high cardiovascular risk, while clinicians receive robust evidence to prioritize aggressive urate‑lowering therapy as a means to prevent heart attacks, strokes, and death.
Ask SkimNews
